Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Int J Mol Med ; 46(1): 3-16, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-2225841

ABSTRACT

In the current context of the pandemic triggered by SARS-COV-2, the immunization of the population through vaccination is recognized as a public health priority. In the case of SARS­COV­2, the genetic sequencing was done quickly, in one month. Since then, worldwide research has focused on obtaining a vaccine. This has a major economic impact because new technological platforms and advanced genetic engineering procedures are required to obtain a COVID­19 vaccine. The most difficult scientific challenge for this future vaccine obtained in the laboratory is the proof of clinical safety and efficacy. The biggest challenge of manufacturing is the construction and validation of production platforms capable of making the vaccine on a large scale.


Subject(s)
Betacoronavirus/immunology , Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Viral Vaccines , COVID-19 , COVID-19 Vaccines , Coronavirus Infections/classification , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Drug Compounding/methods , Drug Compounding/standards , Drug Compounding/trends , Drug Development/methods , Drug Development/standards , Drug Development/trends , Humans , Patient Safety , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , SARS-CoV-2 , Treatment Outcome , Vaccination/adverse effects , Vaccine Potency , Viral Vaccines/classification , Viral Vaccines/standards , Viral Vaccines/supply & distribution , Viral Vaccines/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL